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Dear Editor,
I read with great interest the article by Sostak et al. [1].
This work shows that botulinum toxin markedly sup-
presses cluster headache. I would like to complete the
discussion of Sostak et al. [1] by introducing a major route
through which botulinum toxin could suppress cluster
headache.
Interleukin-1 is a potent prototypical pro-inflammatory
cytokine implicated in the pathogenesis of cluster headache
[2, 3]. Therefore, as described below, the botulinum toxin
minimizes headache by inactivating interleukin-1.
Bacteria produce many enzymes that show extraordi-
nary specificity for mammalian intracellular proteins. The
specificity of these bacterial enzymes has not only made
them a valuable tool for elucidating the cellular functions
of their targets but has also increased our understanding of
protein interactions [4]. Clostridium botulinum is no
exception, producing two classes of enzymes that have
very specific protein targets, neurotoxin A–G and the ADP-
ribosyltransferases C2, C3 bot 1 and C3 bot 2 [4]. C2 and
C3 bot are a part of a larger family of ADP-ribosylating
toxins, including diphtheria toxin and cholera toxin, which
cleave NAD and transfer ADP-ribose to target proteins.
Although the members of this family have homologous
enzymatic domains and similar active sites, these toxins
ribosylate ADP and therefore, disable a range of cellular
targets [4]. Rho family GTPases control the assembly of
both cell–matrix and cell–cell adhesion complexes. IL-1
receptor signaling complex contains these G proteins, and
Rho GTPase is an essential unit for the activation of IL-1
inflammatory pathway. C3 transferase exonzyme specifi-
cally inhibits Rho GTPase by ADP-ribosylation of amino
acid asparagine-41 [5, 6].
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